Name: Latest research reports of Eris Lifesciences Ltd. authored by BOB Capital Markets Ltd. and published by - Trendlyne research reports.
Item: Eris Lifesciences Ltd.
Rating: 5
Author: BOB Capital Markets Ltd.

Eris Lifesciences Ltd.

NSE: ERIS | BSE: 540596 | ISIN: INE406M01024 | Industry: Pharmaceuticals
| Expensive Performer

1464.6000 -17.80 (-1.20%)

NSE May 16, 2025 15:31 PM

79.52% Gain from 52W Low

Volume: 57,235

Eris Lifesciences Ltd.

22 May 2024

1464.60

-1.20%

Eris Lifesciences (BUY): Strong revenue growth; integration ongoing

Buy: Eris Lifesciences Ltd.

Target

BOB Capital Markets Ltd.

ERIS posted strong revenue performance in Q4 with a beat of 8%, but EBITDA came below BBG consensus due to higher opex and one-offs

Number of FII/FPI investors increased from 172 to 178 in Mar 2025 qtr.